Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 112: 129915, 2024 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-39127242

RESUMEN

Many reports have shown that stabilization of secondary structure by stapling functional peptides enhances the intracellular bioactivity. However, no report has discussed the correlation between stabilization and biological activity based on the configuration of amino acid residues used as anchors for stapling. To clarify this, we investigated the helix content and apoptotic efficiency of an apoptosis-inducing peptide, Bim, and four stapled Bim peptides containing stapling-related Cys residues introduced with different configurations within the sequence. The results demonstrated that the configuration of Cys residues in stapled Bim peptides affected the secondary structure and intracellular activity of the peptides, and furthermore, there was a correlation between these latter two variables.


Asunto(s)
Apoptosis , Proteína 11 Similar a Bcl2 , Cisteína , Péptidos , Estructura Secundaria de Proteína , Apoptosis/efectos de los fármacos , Cisteína/química , Proteína 11 Similar a Bcl2/metabolismo , Proteína 11 Similar a Bcl2/química , Humanos , Péptidos/química , Péptidos/farmacología , Péptidos/síntesis química , Relación Estructura-Actividad
2.
Cell Stem Cell ; 24(4): 566-578.e7, 2019 04 04.
Artículo en Inglés | MEDLINE | ID: mdl-30853558

RESUMEN

Induced pluripotent stem cells (iPSCs) have strong potential in regenerative medicine applications; however, immune rejection caused by HLA mismatching is a concern. B2M gene knockout and HLA-homozygous iPSC stocks can address this issue, but the former approach may induce NK cell activity and fail to present antigens, and it is challenging to recruit rare donors for the latter method. Here, we show two genome-editing strategies for making immunocompatible donor iPSCs. First, we generated HLA pseudo-homozygous iPSCs with allele-specific editing of HLA heterozygous iPSCs. Second, we generated HLA-C-retained iPSCs by disrupting both HLA-A and -B alleles to suppress the NK cell response while maintaining antigen presentation. HLA-C-retained iPSCs could evade T cells and NK cells in vitro and in vivo. We estimated that 12 lines of HLA-C-retained iPSCs combined with HLA-class II knockout are immunologically compatible with >90% of the world's population, greatly facilitating iPSC-based regenerative medicine applications.


Asunto(s)
Sistemas CRISPR-Cas/genética , Edición Génica , Antígenos HLA/genética , Histocompatibilidad/inmunología , Células Madre Pluripotentes Inducidas/inmunología , Células Madre Pluripotentes Inducidas/metabolismo , Animales , Línea Celular , Femenino , Antígenos HLA/inmunología , Humanos , Masculino , Ratones , Ratones Endogámicos NOD
3.
Hum Pathol ; 45(4): 717-24, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24485845

RESUMEN

Mucinous tumors of the ovary are frequently associated with mature cystic teratomas, and it has been speculated that the mucinous tumors arise from teratoma components. The cellular origins of mature cystic teratomas are believed to be post-meiotic ovarian germ cells, and the analysis of microsatellite markers such as short tandem repeats is suitable for determining the cellular origin of tumors. In this study, we analyzed 3 ovarian mature cystic teratomas, all of which were associated with simultaneous ovarian mucinous tumors within the same ovary. Two of the 3 mucinous tumors were intestinal-type and the other was endocervical type. A laser capture microdissection technique was used to separate the epithelial component of the mucinous tumor, the components of the mature cystic teratoma, and control ovarian somatic tissue. Using short tandem repeat analysis based on 6 markers (D20S480, D6S2439, D6S1056, D9S1118, D4S2639, and D17S1290), we could distinguish the germ cell (homozygous) or somatic (heterozygous) origin of a given component in each sample. The epithelial components of the intestinal-type mucinous tumors in cases 1 and 2 were homozygous, and the epithelial component in case 3 (endocervical type) was heterozygous. All teratomatous components were homozygous, and the control components were heterozygous. In addition, we analyzed 3 mature cystic teratomas without mucinous tumors, and all 3 were homozygous in the tumor component. Our data suggest that the origin of mucinous tumors in the ovary may differ among histological subtypes, and intestinal-type mucinous tumors may arise from mature cystic teratomas, although endocervical-type mucinous tumors may not.


Asunto(s)
Adenocarcinoma Mucinoso/genética , Neoplasias Primarias Múltiples/genética , Neoplasias Ováricas/genética , Teratoma/genética , Adenocarcinoma Mucinoso/patología , Adulto , Femenino , Humanos , Captura por Microdisección con Láser , Repeticiones de Microsatélite , Persona de Mediana Edad , Neoplasias Primarias Múltiples/patología , Neoplasias Ováricas/patología , Teratoma/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA